Aclid, founded in New York City, is a biotechnology security and compliance automation platform. The company’s core mission is to enhance the safety and regulatory adherence of gene synthesis processes. Aclid offers services that include customer verification, real-time screening of DNA and RNA orders for pathogenic and hazardous elements, and automated compliance inspections. The platform primarily targets gene synthesis companies, ensuring their operations meet stringent safety and regulatory standards.
Notable figures associated with Aclid include experts in biotechnology and cybersecurity, although specific names are not publicly highlighted. The company has secured investments from leading venture capital firms specializing in biotech innovations. Key achievements include the successful deployment of their platform across multiple gene synthesis firms, significantly reducing compliance-related risks and enhancing operational efficiency. Aclid’s impact lies in its ability to streamline safety protocols, thereby fostering a more secure and compliant biotech industry.
